Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Its core activity has a significant growth potential and sales are expected to surge, according to Thomson Reuters' forecast. Indeed, those may increase by 40% by 2021.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The stock is in a well-established, long-term rising trend above the technical support level at 20.34 EUR
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The stock is close to a major daily resistance at EUR 25.45, which should be gotten rid of so as to gain new appreciation potential.
  • Based on current prices, the company has particularly high valuation levels.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 67.08 times its estimated earnings per share for the ongoing year.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, EPS estimates made by Thomson-Reuters analysts have been revised downwards.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC SE41.66%3 664
IQVIA HOLDINGS INC35.52%26 223
LONZA GROUP28.39%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION36.69%17 061
EXACT SCIENCES CORPORATION80.30%13 037
SEATTLE GENETICS, INC.24.67%10 947
IONIS PHARMACEUTICALS INC18.09%9 108
QIAGEN18.17%8 762
SAGE THERAPEUTICS INC84.60%8 652
ICON PLC14.83%7 577
BIO-TECHNE CORP45.23%7 497
ALNYLAM PHARMACEUTICALS, IN..-1.52%7 124
GALAPAGOS40.02%6 305
GALAPAGOS NV (ADR)38.87%6 298
CHARLES RIVER LABORATORIES ..22.16%6 016
More Results
Financials (€)
Sales 2019 417 M
EBIT 2019 73,7 M
Net income 2019 53,5 M
Finance 2019 3,00 M
Yield 2019 -
P/E ratio 2019 67,08
P/E ratio 2020 65,60
EV / Sales 2019 8,82x
EV / Sales 2020 7,66x
Capitalization 3 686 M
Upcoming event on EVOTEC SE
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes